DE69329247T2 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
DE69329247T2
DE69329247T2 DE69329247T DE69329247T DE69329247T2 DE 69329247 T2 DE69329247 T2 DE 69329247T2 DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T2 DE69329247 T2 DE 69329247T2
Authority
DE
Germany
Prior art keywords
csf
csfα
dimer
polypeptide
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329247T
Other languages
German (de)
English (en)
Other versions
DE69329247D1 (de
Inventor
Andrew Bohm
Lisa Fear
Robert Halenbeck
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Jayvardhan Pandit
Eric Taylor
Ralph Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California
Original Assignee
University of California
Chiron Corp
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Chiron Corp, University of California Berkeley filed Critical University of California
Application granted granted Critical
Publication of DE69329247D1 publication Critical patent/DE69329247D1/de
Publication of DE69329247T2 publication Critical patent/DE69329247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69329247T 1992-06-09 1993-06-09 Kristallisierung von m-csf Expired - Lifetime DE69329247T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (2)

Publication Number Publication Date
DE69329247D1 DE69329247D1 (de) 2000-09-21
DE69329247T2 true DE69329247T2 (de) 2001-05-31

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329247T Expired - Lifetime DE69329247T2 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (show.php)
EP (2) EP0668914B1 (show.php)
JP (2) JPH08507916A (show.php)
AT (1) ATE195553T1 (show.php)
CA (1) CA2137793C (show.php)
DE (1) DE69329247T2 (show.php)
WO (1) WO1993025687A1 (show.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
AU1759501A (en) * 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
MXPA03007042A (es) 2001-02-09 2004-05-24 Genentech Inc Cristalizacion de igf-1.
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
HUE026201T2 (en) * 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
SG185035A1 (en) 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PL3283527T3 (pl) 2015-04-13 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (en) * 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists

Also Published As

Publication number Publication date
US6184354B1 (en) 2001-02-06
WO1993025687A1 (en) 1993-12-23
EP0955365A2 (en) 1999-11-10
US5866114A (en) 1999-02-02
JP2004285076A (ja) 2004-10-14
EP0668914B1 (en) 2000-08-16
CA2137793C (en) 2003-04-22
DE69329247D1 (de) 2000-09-21
ATE195553T1 (de) 2000-09-15
CA2137793A1 (en) 1993-12-23
EP0668914A1 (en) 1995-08-30
JPH08507916A (ja) 1996-08-27
EP0955365A3 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
DE69329247T2 (de) Kristallisierung von m-csf
DE69936105T2 (de) Menschliche tslp nukleinsäuren und polypeptide
DE68916537T3 (de) Herstellung eines insulinähnlichen, wachstümsfaktor bindenden proteins.
DE69024291T2 (de) Rezeptoren für Tumornekrosisfaktor-alpha und -beta
US5326558A (en) Megakaryocytopoietic factor
Hymowitz et al. IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding
DE69014162T2 (de) Morphogenetisches Knochenprotein.
DE69017753T3 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
DE68928043T2 (de) Interleukin-4-Rezeptoren
DE68929387T2 (de) Interleukin-1-Inhibitoren
DE3789859T2 (de) Formen des Koloniestimulierungsfaktors 1.
DE3856238T2 (de) DNA, die für Proteine kodiert, die menschliches IL-1 binden
Schreuder et al. Refined crystal structure of the interleukin‐1 receptor antagonist: presence of a disulfide link and a cis‐proline
DE69016508T2 (de) Interleukin-7-Rezeptoren.
DE69229862T2 (de) Cysteinfreie il-6 mutanten
DE69326255T2 (de) Elam-1 bindende peptide und zusammensetzungen
DE69636052T2 (de) Mpl-liganden analoga
US6025146A (en) Identification of M-CSF agonists and antagonists
DE69020161T2 (de) Rezeptoren für granulozytenkolonien stimulierenden faktor.
DE60320304T2 (de) Kristallstruktur von menschlichem il-18
AU640686B2 (en) A megakaryocytopoietic factor
DE60032598T2 (de) Il-1 eta dna und polypeptide
Rodseth et al. Two crystal forms of the extracellular domain of type I tumor necrosis factor receptor
DE69932259T2 (de) Il-1zeta, il-1zeta spleissvarianten, und xrec2 dnas und polypeptide
DE69932247T2 (de) Menschliches il-1 epsilon dna und polypeptide

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, O, US